权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Systems Pharmacology Model for Spatial Control of Cardiac Fibrosis

心脏纤维化空间控制的系统药理学模型

基本信息

批准号：
9363220
负责人：
JEFFREY W HOLMES
金额：
$ 47.97万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-07-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9363220
关键词：
Acute Address American Arrhythmia Cardiac Cell model Cells Cicatrix Collagen Computer Simulation Congestive Heart Failure Databases Deposition Devices Drug Combinations Drug Controls Drug Targeting Educational workshop Employee Strikes Environment Event Experimental Models Extracellular Matrix Extracellular Protein Failure Fibroblasts Fibrosis Goals Heart Heart failure Heterogeneity Impairment In Vitro Individual Infarction Inflammation Inflammatory Injectable Injury Left Life Location Modeling Muscle Myocardial Infarction Myocardium National Heart, Lung, and Blood Institute Organ Pharmaceutical Preparations Pharmacology Polymers Preclinical Drug Evaluation Preparation Pump Rattus Regimen Regulation Risk Rupture Series Signal Transduction Site Specificity System Testing Time United States National Institutes of Health Ventricular Ventricular Fibrillation Vision Wound Healing base coronary fibrosis experience experimental study healing heart pharmacology improved in vivo injured innovation interstitial molecular drug target multi-scale modeling network models novel novel strategies novel therapeutic intervention response spatiotemporal virtual

项目摘要

The majority of individuals that initially survive a myocardial infarction go on to suffer from life-threatening complications such as infarct rupture, arrhythmia, or heart failure. These sequelae depend critically on wound healing in the infarct as well as fibrosis in the remote myocardium, yet existing drugs are not designed to specifically target either of these. An ideal pharmacologic therapy would enhance extracellular matrix in the infarct while reducing fibrosis in the remote myocardium, but achieving such spatial control of extracellular matrix has eluded the field. We propose that these distinct local responses to globally applied drugs can be achieved by leveraging environment-dependent signaling mechanisms, uniquely identified with systems pharmacology models. We first integrate drug-target interaction databases together with a novel large-scale model of the cardiac signaling network to identify drugs or drug pairs that cause context-dependent regulation of extracellular matrix with cultured cardiac fibroblasts. We then integrate the signaling network model with agent-based models of inflammation and myocardial infarct healing. This integrated model is applied to perform multi-scale virtual drug screening to predict and then experimentally validate drugs that enhance extracellular matrix in the infarct while reducing fibrosis in the remote myocardium. Overall, this study will provide an innovative framework for multi-scale systems pharmacology of cardiac fibrosis, identify new therapeutic approaches for infarct healing, and provide proof-of-concept for spatial control of drug responses by leveraging context-dependent cell signaling.

大多数最初在心肌梗死中存活的个体继续遭受危及生命的心肌梗死。并发症如梗塞破裂、心律失常或心力衰竭。这些后遗症主要取决于伤口治疗梗塞以及远端心肌纤维化，但现有药物的设计并不专门针对其中任何一个。理想的药物治疗将提高细胞外基质在梗死，同时减少远端心肌纤维化，但实现这种空间控制的细胞外矩阵已经避开了场。我们建议，这些不同的地方反应，全球应用的药物，可以是通过利用依赖于环境的信令机制来实现，药理学模型我们首先将药物-靶点相互作用数据库与一种新的大规模心脏信号网络的模型，以识别引起环境依赖性调节的药物或药物对细胞外基质与培养的心脏成纤维细胞。然后，我们将信令网络模型与基于药物的炎症和心肌梗死愈合模型。该集成模型适用于进行多尺度虚拟药物筛选，以预测并通过实验验证能够增强细胞外基质，同时减少远端心肌纤维化。总的来说，这项研究将为心脏纤维化的多尺度系统药理学提供创新框架，治疗方法的梗死愈合，并提供了概念验证的空间控制药物反应通过利用上下文相关的小区信令。